No Data
No Data
Novo Nordisk, Flagship to Develop Next-generation Obesity Drugs
Seres Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 412.89% Oppenheimer $5 → $4 Maintains Outperform 05/08/2024 669.33% Chardan Capital $8 → $6 Mai
12 Health Care Stocks Moving In Thursday's Intraday Session
GainersEmbecta (NASDAQ:EMBC) shares increased by 37.7% to $14.14 during Thursday's regular session. The company's market cap stands at $814.1 million. As per the press release, Q2 earnings came out to
Seres Therapeutics Is Maintained at Buy by Chardan Capital
Seres Therapeutics Is Maintained at Buy by Chardan Capital
Express News | Seres Therapeutics : Oppenheimer Cuts Target Price to $4 From $5
Buy Rating Affirmed for Seres Therapeutics Amidst Strong Sales Trajectory and Promising Pipeline